Anti-Human CD3 x CD20 (Epcoritamab) - 25 mg

All|Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

Epcoritamab is a CD20xCD3 Bispecific T cell Engager (BiTE) antibody developed as acancer immunotherapeutic drug 1 . Simultaneous targeting of CD20 B cell onlymphomas and CD3 on T cells, leads to T cell activation, the release of perforin andgranzymes, and ultimately the depletion of malignant B cells through lysis and celldeath 1 . This approach is potent in treating B-cell malignancies like non-Hodgkin lymphoma.The distribution of Anti-Human CD3 x CD20 includes blood and lymphatic tissues, enablingeffective engagement with T and B-cells, enhancing its therapeutic efficacy2-4. Epcoritamab (GEN3013) is a bispecific antibody that targets CD3 on T-cells and CD20 on B-cells, inducing potent T-cell-mediated cytotoxicity against CD20-expressing B-cells.Administered subcutaneously, Epcoritamab has demonstrated significant efficacy in clinicaltrials for relapsed or refractory B-cell lymphomas. In laboratory settings, Epcoritamab isutilized to study bispecific antibody mechanisms and develop therapeutic strategies for B-cellmalignancies5-7.

≥ 5.0 mg/ml

CD20 is widely expressed on normal B cells during all stages ofdevelopment, as well as by most B cell malignancies. CD3 is a T cell surfaceglycoprotein.